Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 5/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11948729 | 0.84 | HPGD (0.38) | TRPV4ARHPGDALDH1A1 | |
| SCHEMBL18315128 | 0.78 | TSHR (0.38) | EGLN2TRPV4ARHPGDALDH1A1 | |
| SCHEMBL8111333 | 0.78 | GPR35 (0.41) | TRPV4ARHPGDALDH1A1 | |
| SCHEMBL14033196 | 0.78 | TRPV4 (0.39) | KHKCYP11B1CYP11B2TRPV4AR | |
| SCHEMBL13525263 | 0.78 | DHODH (0.40) | KHKCYP11B1CYP11B2TRPV4AR | |
| SCHEMBL31218431 | 0.78 | KHK (0.41) | KHKEGLN2CYP11B1CYP11B2TRPV4 | |
| SCHEMBL22120133 | 0.78 | KHK (0.41) | KHKEGLN2CYP11B1CYP11B2TRPV4 | |
| SCHEMBL20267322 | 0.78 | KHK (0.41) | KHKEGLN2CYP11B1CYP11B2TRPV4 | |
| SCHEMBL11981507 | 0.77 | TRPV4 (0.38) | KHKEGLN2CYP11B1CYP11B2TRPV4 | |
| SCHEMBL10144167 | 0.77 | TSHR (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258329-B2 | Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells | MERCK SHARP & DOHME LLC (US) | 2025-03-25 | — | — | US | disclosed |
| CN-114026081-B | Pyridone derivatives as selective cytotoxic agents against HIV-infected cells | 默沙东有限责任公司 | 2025-02-11 | — | — | CN | disclosed |
| EP-3972965-B1 | PYRIDINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | MERCK SHARP & DOHME LLC (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-3898595-B1 | PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | MERCK SHARP & DOHME LLC (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20220242847-A1 | PYRIDINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | MERCK SHARP & DOHME CORP. (US) | 2022-08-04 | — | — | US | disclosed |
| EP-3972965-A1 | PYRIDINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | Merck Sharp & Dohme Corp. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20220064147-A1 | PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | MERCK SHARP & DOHME CORP. (US) | 2022-03-03 | — | — | US | disclosed |
| CN-114026081-A | Pyridone derivatives as selective cytotoxic agents against HIV-infected cells | 默沙东公司 | 2022-02-08 | — | — | CN | disclosed |
| EP-3898595-A1 | PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | Merck Sharp & Dohme Corp. (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-113423695-A | Pyrimidinone derivatives as selective cytotoxic agents against HIV infected cells | 默沙东公司 | 2021-09-21 | — | — | CN | disclosed |
| US-8691847-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-04-08 | — | — | US | disclosed |
| US-20130172310-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. | 2013-07-04 | — | — | US | disclosed |
| US-20120083602-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. | 2012-04-05 | — | — | US | disclosed |
| US-8063036-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100298284-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-7727981-B2 | monoamidino-containing compounds having good bioavailability and/or solubility, used as potent and specific inhibitors of blood coagulation in mammals, and as therapeutic agents for disease states characterized by coagulation disorders | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727982-B2 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090131411-A1 | monoamidino-containing compounds having good bioavailability and/or solubility, used as potent and specific inhibitors of blood coagulation in mammals, and as therapeutic agents for disease states characterized by coagulation disorders | MILLENNIUM PHARMACEUTICALS, INC. | 2009-05-21 | — | — | US | disclosed |
| US-7314874-B2 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide;modified amidine elements of high potency in vitro, excellent pharmacological and pharmaceutical properties in vivo | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064147-A1 | PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | TYMP, PNP, CD4 | KHK 3409/4885EGLN2 3722/4885CYP11B1 3424/4885 |
| US-20090131411-A1 | monoamidino-containing compounds having good bioavailability and/or solubility, used as potent and specific inhibitors of blood coagulation in mammals, and as therapeutic agents for disease states characterized by coagulation disorders | F12, F2, PIGS | KHK 1836/4885EGLN2 873/4885CYP11B1 2931/4885 |
| US-20100298284-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | KHK 1072/4885EGLN2 479/4885CYP11B1 3476/4885 |
| US-20120083602-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | KHK 1072/4885EGLN2 479/4885CYP11B1 3476/4885 |
| US-20130172310-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | KHK 1072/4885EGLN2 479/4885CYP11B1 3476/4885 |
| US-20220242847-A1 | PYRIDINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | PRUNE1, G6PD, ACIN1 | KHK 1899/4885EGLN2 3832/4885CYP11B1 2047/4885 |
| US-12258329-B2 | Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells | TYMP, PNP, CD4 | KHK 3409/4885EGLN2 3722/4885CYP11B1 3424/4885 |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | F2, TFPI, PLG | KHK 1163/4885EGLN2 320/4885CYP11B1 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.